Fiduciary Trust’s Dianthus Therapeutics DNTH Stock Holding History

Fiduciary Trust’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,910	Closed	-$23.2K	–	615
2023 Q2	$23.2K	Hold	1,910	–	–	﹤0.01%	623
2023 Q1	$24.3K	Hold	1,910	–	–	﹤0.01%	613
2022 Q4	$12.1K	Hold	1,910	–	–	﹤0.01%	625
2022 Q3	$43K	Hold	1,910	–	–	﹤0.01%	601
2022 Q2	$37K	Hold	1,910	–	–	﹤0.01%	622
2022 Q1	$89K	Hold	1,910	–	–	﹤0.01%	653
2021 Q4	$135K	Hold	1,910	–	–	﹤0.01%	646
2021 Q3	$222K	Buy	1,910 +35	+2%	+$4.08K	﹤0.01%	609
2021 Q2	$293K	Hold	1,875	–	–	0.01%	560
2021 Q1	$355K	Hold	1,875	–	–	0.01%	508
2020 Q4	$235K	Hold	1,875	–	–	﹤0.01%	536
2020 Q3	$204K	Hold	1,875	–	–	﹤0.01%	528
2020 Q2	$225K	Buy	1,875 +312	+20%	+$44K	0.01%	500
2020 Q1	$157K	Buy	1,563 +625	+67%	+$116K	﹤0.01%	479
2019 Q4	$227K	Hold	938	–	–	0.01%	485
2019 Q3	$154K	Hold	938	–	–	﹤0.01%	502
2019 Q2	$221K	Buy	+938	New	+$232K	0.01%	468

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Fiduciary Trust's DNTH Position: Q3 2023 in Review

Fiduciary Trust sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 1,910 shares — an estimated $23.2K sold.

Fiduciary Trust first reported a position in DNTH in Q2 2019 and held it in 17 quarters. The position peaked at $355K in Q1 2021. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

Fiduciary Trust reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
Fiduciary Trust sold 1,910 Dianthus Therapeutics shares in Q3 2023, an estimated $23.2K.
Fiduciary Trust first reported a position in Dianthus Therapeutics in Q2 2019 and held it in 17 quarters.
Fiduciary Trust's Dianthus Therapeutics position peaked at $355K in Q1 2021.
30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Fiduciary Trust's 13F filing for Q3 2023, filed 14 Nov 2023.